NCT05818982View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions
Advanced Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Afatinib

Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.

DRUG

Irinotecan

Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D

Trial Locations (3)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing, China, Beijing

NOT_YET_RECRUITING

First Hospital of Xiamen University Affiliated Hospital,Xiamen,China, Xiamen

NOT_YET_RECRUITING

Xinxiang Central Hospital of Henan Province, Xinxiang, China, Xinxiang

All Listed Sponsors
lead

Peking University

OTHER